Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose- Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer.

Trial Profile

Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose- Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 May 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Paclitaxel (Primary)
  • Indications Breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Mar 2018 Status changed from completed to active, no longer recruiting.
    • 29 Mar 2018 Planned End Date changed from 1 Aug 2013 to 1 Oct 2018.
    • 12 Dec 2015 Results (n=443) presented at the 38th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top